Concepedia

Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis

Srikanth Muppidi, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn, Isabel Illa, Saiju Jacob, John Vissing, Ted M. Burns, John T. Kissel,

Muscle & Nerve · 2019 · 239 citations · 32 references

DOIFull text

Open access

Abstract

These findings provide evidence for the long-term safety and sustained efficacy of eculizumab for refractory gMG. Muscle Nerve 2019.

References

32

The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Peter Hillmen, Neal S. Young, Jörg Schubert et al. · New England Journal of Medicine · 2006 · 1.2K citations · Full text

Antibody to acetylcholine receptor in myasthenia gravis

Jon Lindstrom, Marjorie E. Seybold, Vanda A. Lennon et al. · Neurology · 1976 · 1.2K citations · Full text

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Russell P. Rother, Scott A. Rollins, Christopher F. Mojcik et al. · Nature Biotechnology · 2007 · 752 citations

, , +5

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

, , +3

Myasthenia gravis: recommendations for clinical research standards

Alfred Jaretzki, Richard J. Barohn, Raina M. Ernstoff et al. · The Annals of Thoracic Surgery · 2000 · 638 citations · Full text